Evidence map›Paper›PMID 21793914›Full record

Trial reportJournal of gastroenterology and hepatology2012

Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study.

Taraq A Attumi, David Y Graham

Abstract readClinical Trial
In one paragraph

Trial report in Journal of gastroenterology and hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Vonoprazan-amoxicillin dual therapy forWorld journal of gastroenterology · 2024
    Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Taraq A AttumiDepartment of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
David Y Graham

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
REGULATION OF CXC CHEMOKINE EXPRESSION BY H. PYLORIR01DK062813 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI YAMAOKA, YOSHIO · 2004 to 2013
$3.0M
Obesity, H pylori and Risk of Barrett's EsophagusR01CA116845 · NCI · BAYLOR COLLEGE OF MEDICINE · PI EL-SERAG, HASHEM B · 2007 to 2011
$2.8M
Gene Expression in Barrett's EsophagusR21DK067366 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI EL-SERAG, HASHEM B · 2005 to 2006
$296k
NCI NIH HHS CA116845NCI NIH HHS R01 CA116845NIDDK NIH HHS DK067366NIDDK NIH HHS DK56338NIDDK NIH HHS P30 DK056338NIDDK NIH HHS R01 DK062813NIDDK NIH HHS R21 DK067366
6 · The paper itself

Abstract

BACKGROUND AND

aimHelicobacter pylori infections have become increasingly difficult to treat as antimicrobial resistance has increased. The aim of this study was to test the hypothesis that a 6-week dual regimen of amoxicillin 1 gm and omeprazole 20 gm therapy b.i.d. would cure at least 90% of treatment-naïve H. pylori infections.

methodsThis was an open-label prospective pilot study in which treatment-naïve subjects with active H. pylori infection (positive by two tests) received dual amoxicillin 1 g and omeprazole 20 mg, b.i.d. daily for 6 weeks. Success was accessed by urea breath test 4-6 weeks later. A tentatively effective therapy was defined as a per-protocol treatment success of 90% or greater; treatment success of 80% or less was prespecified as unacceptable.

resultsSixteen patients were included in the study (14 men, two women) with an average age of 49 years. At 16 patients, the prespecified stopping rule of six treatment failures was achieved (i.e. the 95% confidence interval excluded achieving the required 90% success rate even if 50 patients were entered). As per protocol, enrollment was stopped. Per-protocol and intention-to-treat treatment success were both 62.5% (95% confidence interval, 35-84%). Compliance was greater than 99%. Five patients (31%) reported side-effects, all of which were mild and none interrupted therapy.

conclusionDespite the theory and pre-existing data from Japan, in the USA, prolonging the duration of dual amoxicillin-PPI therapy did not improve treatment outcome in 90% or more of our patients.

Indexed as

AmoxicillinAnti-Bacterial AgentsBreath TestsDrug Administration ScheduleDrug Therapy, CombinationFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMedication AdherenceMiddle AgedOmeprazolePilot ProjectsProspective StudiesProton PumpsAmoxicillinAnti-Bacterial AgentsOmeprazoleProton Pumps

Identifiers

PMID21793914
PMCPMC3212627

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.